The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Published Online:

T he differential diagnosis of patients who experience symptoms of paresthesias, derealization, dizziness, chest pain, tremors, and palpitations can be quite challenging. These symptoms occur across a wide range of disorders, including cardiac, psychiatric, and neurological disorders. It can be particularly difficult to differentiate partial seizures without generalization of temporal lobe origin from panic disorder, as all of the above symptoms can be found in both conditions. 7 , 8 In fact, panic disorder has been found to be the most common condition that must be distinguished from seizure disorder. 9 The possibility that panic disorder and temporal lobe epilepsy with ictal fear can be comorbid has also been raised. 10

Panic disorder occurs in 1% to 3% of the population. Older estimates place the incidence of seizures at 0.03%, with ictal fear occurring in one-third of these patients. 11 , 12 New estimates place lifetime incidence of epilepsy at 3%. 13 Although a rare occurrence, multiple case reports have documented that patients initially diagnosed with panic disorder may later receive a diagnosis of temporal lobe seizures. Initial patient presentation can be quite varied. 1418 It has been proposed that panic attacks with an onset consistent with an epileptic aura may sometimes be the result of simple partial seizures with a psychological presentation. 19 This hypothesis is supported by several lines of evidence, including concomitant symptoms, multiple cases with initial diagnosis of panic disorder but eventual electroencephalographic (EEG) documentation of seizures, comorbidity of the two conditions, nonepileptic EEG abnormalities in panic disorder, the proposed amygdala-driven kindling of the fear network, and limited clinical data suggesting successful treatment of panic attacks with antiepileptic medications. 19

The literature does provide guidance for distinguishing between these two conditions: 8 , 11 panic attacks are generally longer in duration than seizures; ictal episodes are more stereotyped, whereas panic episodes are likely to vary more in presentation; although seizure disorders may initially present with fear/anxiety, they may progress to the more classic symptoms (e.g., olfactory auras, aphasias, amnestic features, motionless state, visceral automatisms); initial presentation of these classic epileptic features (i.e., before the fear/panic feelings) suggests seizures; panic disorder is more likely associated with agoraphobia (50% of cases); panic disorder has stronger familial links (25% for first-degree relatives); panic disorder can be worsened by emotional distress; presence of temporal lobe lesions on imaging can indicate epilepsy; and some treatments for panic disorder can worsen seizures (e.g., tricyclic antidepressants). 8 , 9 If the presentation is suggestive of epilepsy, EEG examination may be required to identify the characteristic spike/wave pattern of seizure discharge. A full evaluation for epilepsy may require 24-hour EEG and video monitoring or intracerebral depth electrodes with subdural grid arrays, as these procedures can sometimes identify abnormal electrical discharges not observed on routine EEG. 18 , 20 , 21 High resolution magnetic resonance imaging (MRI) is recommended for visualization of the deep temporal lobe structures. 2 , 22 This is particularly important for reliable separation of the amygdala and hippocampus in order to obtain accurate volume measurements. 23 Given the similar clinical features and divergent treatments for these two diagnoses, it is imperative for the clinician to understand the neuroanatomical features of the temporal lobe and the noninvasive imaging techniques available to assist in decision-making.

Anatomy of the Temporal Lobe

The mesial temporal lobe contains structures that are part of the limbic circuits, including the amygdala and hippocampus ( Figure 1 ). 1 , 2 , 24 These structures have been implicated in the genesis of both panic disorder and seizure disorders. 8 , 9 , 18 Fear and panic have been elicited by electrical stimulation of the amygdala. 2529 These symptoms can also occur as the initial symptoms of temporal lobe discharges. 7 , 14 , 30 Abnormal electrical activity in the frontal lobes, due either to spread from the temporal lobe or to a frontal focus, has also been found to be associated with fear or panic. 30

FIGURE 1. The location and extent of the temporal lobe (pink), the hippocampus (green) and the amygdala (blue) are color-coded onto a lateral drawing of the brain and representative coronal and axial magnetic resonance (MR) images. Landmarks commonly used for identification of the boundary between the amygdala and anterior hippocampus are labeled in yellow. 1,2 The dashed lines on the lateral view of the brain indicate the locations and orientations for the two MR sections.

Structural Imaging

Temporal Lobe Epilepsy

It is a common finding that temporal lobe structures, particularly the hippocampus and amygdala, are decreased in volume in patients with temporal lobe epilepsy. 23 , 31 One study reported that amygdala volume was more decreased in temporal lobe epilepsy patients who reported experiencing fear during seizure onset than in those who did not. 32 However, a later study from the same group did not confirm this association. 33

Panic Disorder

Earlier studies compared volumetric measurement of temporal lobe structures between patients with panic disorder and healthy individuals based upon edge-tracing regions-of-interest. 3436 One study reported that only the amygdala was decreased in size (bilaterally). 34 This study found no differences in the volumes of the hippocampus or the whole temporal lobe, and no anatomic measure correlated significantly with any clinical or demographic measure. In contrast, two studies found the volume of the temporal lobe (on the left in one, bilaterally in the other) was significantly decreased, but not the volume of the hippocampus or amygdala. 35 , 36 One study found a perplexing inverse correlation between duration of panic disorder and hippocampal volume, with a more recent onset associated with a smaller hippocampus. 35 Recently, several groups have utilized voxel-based morphometry to compare gray matter volumes of patients with panic disorder (diagnosis confirmed by a structured clinical interview [SCID], no mention made of any EEG studies) to healthy individuals. 3739 With strict statistical criteria applied, there is little agreement, with one study reporting decreased gray matter only in the parahippocampal gyrus, the second reporting decreases only in the putamen, and the third reporting increased gray matter in several areas of the brainstem as well as ventral hippocampus. With less stringent statistical criteria, decreased gray matter volume was also found in the inferior and superior frontal and temporal gyri, and increased gray matter volume was found in the middle temporal gyrus in at least two of the three studies, although the laterality was not always the same. None reported changes in the amygdala. An inverse correlation was reported between volume of the putamen and clinical symptoms, with a lower volume associated with greater symptom severity and illness duration. 38

The diversity of these findings may be due, at least in part, to differences in the measurement techniques employed. Edge-tracing region-of-interest analysis is based on the recognition of anatomic landmarks that are used to hand-trace regions onto magnetic resonance images. This approach has the advantage that individual differences in anatomy can be easily taken into account. It is also stronger statistically, because fewer comparisons need to be made. However, fewer areas can be assessed. Anatomic criteria and anatomic expertise vary across studies. Image resolution and section thickness also vary, a critical factor when small structures, such as the amygdala, are measured. Voxel-based morphometry provides a method of automatic analysis of the entire brain, allowing many more areas to be compared. However, this creates a statistical challenge. The likelihood of getting a false positive increases with the number of comparisons made. A mathematical correction for multiple comparisons must be performed. This approach also requires transformation of each individual’s data onto an average brain template, which inevitably results in some distortion of individual anatomy, and often in some loss in image resolution, particularly if smoothing is also performed. In addition, image voxels are relatively large in terms of the size of many structures in the brain. If 1-mm sections with an in-plane resolution of 1-mm are acquired, for example, the cortical ribbon would be no more than three voxels wide. As a result, many voxels contain both gray and white matter, and partial-volume averaging is inevitable.

Finally, there is also diversity across studies including patient population and medication status. It should also be noted that EEG was not used to rule out any electrical abnormalities. As noted above, temporal lobe epilepsy has also been associated with reduced amygdala volumes as well as multiple areas of temporal lobe injuries.

Functional Imaging—Cerebral Blood Flow/Cerebral Metabolism

Given the common abnormal structural findings in both conditions, functional imaging may be needed to further inform the differential for panic disorder from temporal lobe epilepsy.

Temporal Lobe Epilepsy

During an epileptic seizure (ictus) there is an increase in both blood flow and metabolism in the seizure focus. Generally, seizures are brief, lasting only seconds to minutes. During the immediate postictal period, there is a drastic fall to a state of severe hypoperfusion. This is followed by a gradual recovery to a lessened level of hypoperfusion, which becomes the new resting state. This sequence is called the “postictal switch.” Thus, interictally, there is a general hypometabolism in the abnormal area, and at times in the surrounding cortex, subcortical nuclei, or even in the contralateral temporal lobe. Comparative studies indicate that this depressed state deepens with the duration of the seizure disorder, with cerebral metabolism more affected than cerebral blood flow. 40 This mismatch between metabolism and blood flow indicates that 18-fluoro-2-deoxyglucose (FDG) positron emission tomography (PET), which provides images of cerebral metabolic rate, will more accurately delineate the seizure focus for scans acquired during the interictal period than single photon emission tomography (SPECT), which provides images of cerebral blood flow. 40 , 41

Both SPECT and FDG-PET are used to identify areas of seizure focus, evaluate patients for surgical resection of the affected temporal cortex, and to predict clinical outcome postsurgery. 13 , 31 A major advantage of SPECT is the ability to capture ictal activity (i.e., hyperperfusion), due to rapid (e.g., 30 to 60 seconds) radiotracer uptake. 31 Ictal SPECT scans are compared to the interictal SPECT to determine the area of seizure focus (areas that are “hot” during the seizure and “cold” between seizures) ( Figure 2 ). The sensitivity and accuracy of this technique are reported to be approximately 80%. 13 In clinical practice it is likely to be somewhat lower than this. Many research studies include patients for whom nuclear imaging would not be required because the seizure focus can be identified by visualization of lesions on structural images.

FIGURE 2. Nuclear medicine scans obtained during a seizure (ictal scan) will show increased perfusion or metabolism in the epileptic focus (arrows), as illustrated here with both coronal and axial single photon emission computed tomography (SPECT) images of cerebral blood flow. Scans obtained in the absence of seizure (interictal scan) will show decreased perfusion or metabolism (arrows).

FDG-PET has higher image resolution, but radiotracer uptake is generally too slow for ictal imaging. The better spatial resolution of interictal FDG-PET scanning does allow for quantitative evaluation of abnormal areas that can be compared with the structural magnetic resonance (MR) images. Current FDG-PET techniques allow statistical parametric mapping that can identify abnormal areas sometimes not evident on visual interpretation. Both FDG-PET and SPECT are more valuable in conjunction with inpatient video EEG monitoring. Partial-volume averaging may cause small areas of abnormality to artificially appear healthier than they really are. Nonlimbic (nontemporal lobe) seizures are more likely to have normal interictal scans than are limbic/temporal lesions. FDG-PET and SPECT may identify patients who have two independent areas of seizure focus, not identifiable on structural imaging or by EEG data. Additionally, they can identify temporal lobe dysfunction in atypical panic/fear episodes signaling the need for an epilepsy investigation. Two recent case reports illustrate a clinical presentation of atypical fear/panic attacks resulting from mesial temporal sclerosis. In each case, nuclear imaging identified the temporal lobe hypometabolism/hypoperfusion of the epileptic focus. 17 , 42

Areas of abnormal metabolism or blood flow may be present at a distance from the epileptic focus. Statistical parametric mapping was used to assess the extent of both ictal and interictal cerebral blood flow (SPECT) alterations in patients with mesial temporal sclerosis compared with healthy individuals. 43 In addition to the expected increased perfusion in the ipsilateral temporal lobe (including the temporal stem white matter), ictal SPECT identified areas of hyperperfusion in the contralateral temporal lobe, anterior frontal lobe (left-sided focus) and parietal lobe (right-sided focus). Areas of decreased perfusion on interictal SPECT included hippocampus, thalamus, midbrain, superior paracentral lobule, insula (left-sided focus), and cingulate gyrus (right-sided focus). The authors of this study noted that these results are consistent with functional impairment of the cortico-thalamo-hippocampal circuit. A recent study compared the localization of interictal hypometabolism (FDG-PET) with the outcome of surgery. 44 Patients with hypometabolism confined to the temporal cortex containing the focus had better outcomes (78% seizure-free) than patients with hypometabolism in additional ipsilateral areas (45% seizure-free) or contralateral areas (22% seizure-free).

Panic Disorder

Two studies have used statistical parametric mapping to compare cerebral metabolic rate (FDG-PET) of patients with panic disorder (medication free) with healthy individuals ( Figure 3 ). 4 , 6 Both found increases in hippocampus and parahippocampal structures. One also found increases in the thalamus, cerebellum, medulla, and pons. 4 The authors of this study 4 noted that these areas are part of the amygdala-based fear network. The other study found decreases in inferior parietal and superior temporal areas. 6 A third study of medication-free patients with panic disorder utilized visual and semiquantitative analysis of regional cerebral blood flow (SPECT). 5 They found significantly decreased perfusion only in the inferior frontal area ( Figure 3 ). The authors commented that this might be due to an inhibitory influence from the amygdala. None of the above studies reported any correlation between functional imaging findings and clinical symptoms. In contrast, a study that compared cerebral perfusion (SPECT) in medicated patients with panic disorder to healthy individuals found decreases only in the superior temporal lobe ( Figure 3, right ). This study reported an inverse correlation between blood flow and both duration of illness and clinical symptoms (lower perfusion with higher scores). 3 One group performed a second functional imaging examination (FDG-PET) at the conclusion of 10 sessions (over 6 months) of cognitive behavior therapy. 45 Most of the patients (11/12) were responsive to treatment. In comparison with pre-treatment levels, the responsive group exhibited normalization of cerebral metabolism, with decreases in the hippocampus, cerebellum, and pons, and increases in the medial prefrontal cortex bilaterally. Overall, these results are consistent with altered reactivity in the fear circuitry that may normalize with successful treatment.

FIGURE 3. Nuclear medicine scans acquired under resting conditions from patients with panic disorder have areas of increased (yellow, orange) and decreased (blue, green, purple) perfusion or metabolism compared with healthy individuals. 3–6 Reported differences were in the range of 5% to 10%, smaller than is typically seen in epilepsy.

Functional Imaging—Receptor/Neurotransmitter Mapping

As radio-tracers for a variety of neurotransmitter receptors become more widely available, they add yet another nuclear imaging tool that may help to clarify temporal lobe function and pathology. At the present time, ligands for the benzodiazepine-GABA A receptor, the serotonin 5-HT 1A receptor, and the muscarinic acetylcholine receptor have been evaluated for their ability to improve visualization of the epileptic focus. Of these, only a handful of studies utilizing some of these ligands have been performed in patients with panic disorder.

Benzodiazepine-GABA A Receptor

GABA has been known to be associated with the temporal lobe, anxiety disorders, and seizures for many years. 46 , 47 Ligands for the central benzodiazepine-GABA A receptor suitable for both PET (C 11 flumazenil, FMZ) and SPECT (I 123 iomazenil, IMZ) studies are available, although neither is yet approved for clinical use in the United States. 48

Temporal Lobe Epilepsy

Reduced benzodiazepine receptor binding has been demonstrated (by autoradiography) in surgically resected specimens from temporal lobe epilepsy patients. 49 It has not yet been proven that either of the available benzodiazepine ligands is more accurate for delineation of the seizure focus than the functional imaging techniques already in clinical use (as detailed above). 48 , 5052 There are promising indications. When hippocampal sclerosis was present, the area of abnormality was often larger on FDG-PET than on FMZ-PET, which more closely matched the epileptogenic zone as determined by intracranial EEG. 50 A case was recently published in which interictal IMZ SPECT provided correct laterality of the seizure focus (as determined by intracranial EEG) while ictal perfusion SPECT did not. 53 Timing of the examination in relation to seizure activity may be a critical factor, as a recent study found within-subject short-term changes in binding. 54 Lower values (better delineation of seizure focus) were obtained when the FMZ-PET was performed shortly after a seizure, suggesting a transient decrease in expression or availability. Given this evidence for dynamic seizure-related changes, the authors of the study recommend that benzodiazepine receptor imaging be performed within a few days following a seizure for best results. Larger studies in which this factor is taken into account are needed to better assess the value of this technique. Other potentially confounding factors include medication status (many antiepileptic medications affect GABA), comorbid psychiatric diagnoses, and variations in imaging technology.

Panic Disorder

Both increases and decreases in regional benzodiazepine binding have been reported when patients with panic disorder were compared with healthy individuals. 5557 Two studies included only patients with panic disorder that had never taken benzodiazepines. 55 , 56 One, using FMZ-PET and statistical parametric mapping, reported both globally reduced binding and regional decreases in orbital (right) and insular (right) cortices in patients compared with healthy individuals. 55 The other, using IMZ-SPECT and template-based analysis, reported increased binding in orbital cortex (right) and a trend toward increased binding in temporal cortex (right) in patients with panic disorder. 56 The third study included patients with panic disorder who had been medication-free for at least 6 weeks. 58 This IMZ-SPECT study utilized both statistical parametric mapping and region-of-interest analyses. No difference was found in global binding between the patient group and healthy individuals. Binding was decreased in the area of the hippocampus (left) and precuneus (left) and increased in caudate (right), medial frontal cortex (right) and middle temporal gyrus (left) in the patient group. Some patients experienced panic symptoms during scanning. Decreased binding in the medial frontal and superior frontal cortex (Brodmann’s areas 8, 9, 10) correlated with increased symptoms. Diversity across studies may be due to methodological differences and/or variations in the patient population studied. While preliminary, these studies suggest that alterations in benzodiazepine binding in frontal areas may differentiate panic disorder patients from temporal lobe epilepsy patients. Further studies that explore the apparently dynamic relationship between symptom state and binding would be of great value.

Serotonin 5-HT 1A Receptor

Serotonin has been implicated in the pathophysiology of both panic disorder and seizure disorders. 59 , 60 Ligands based on several 5-HT 1A antagonists have been developed for PET imaging (C 11 WAY100635; F 18 trans-4 - fluoro - N - 2 - [4 - (2 - methoxyphenyl)piperazin - 1 - yl]ethyl] - N - (2 - pyridyl)cyclohexanecarboxaminde, FCWAY; F 18 4 - [2’ - (N - 2 - pirydynyl) - p - fluorobenzamido] - ethylpiperazine, MPPF).

Temporal Lobe Epilepsy

Several groups have evaluated 5-HT 1A receptor binding in patients with temporal lobe epilepsy. 6166 All found decreased receptor binding in the mesial temporal lobe containing the seizure focus, in areas of seizure spread, and in the area of the brainstem raphe. Localization was reported to be better than with cerebral blood flow or metabolic rate imaging in some studies. 61 , 62 One group found an inverse correlation between abnormal intracerebral activity and binding potential. 63 The most profound decreases in binding potential were in areas of seizure onset; moderate decreases were found in areas of seizure spread, with only mild decreases in areas of interictal activity. These results are promising, but must still be considered preliminary. The importance of correcting for partial volume averaging and for differences in plasma binding related to antiepileptic medications has been emphasized by one group. 65 , 66

Panic Disorder

One study comparing unmedicated patients with panic disorder to healthy individuals found decreased 5-HT 1A receptor binding in the anterior and posterior cingulate cortices and the raphe area, with no differences in anterior insular, mesiotemporal or anterior temporal cortices. 67 Another reported decreased binding principally in amygdala and orbitofrontal and temporal cortices as well as the raphe area. 68 This study compared binding in an ummedicated patient group with a patient group successfully treated with SSRIs. They reported normalization of binding in all areas except the raphe.

CONCLUSIONS

In conclusion, although the current diagnostic classification defines panic disorder and simple partial seizure disorder as two separate entities, they clearly share similar features and common symptoms and may occur as comorbidities. Rarely, patients diagnosed with panic disorder later show evidence of mesial temporal sclerosis and EEG-proven seizure foci. The close clinical presentations of these two conditions call for a very thorough medical evaluation of those patients with preliminary suspicions of panic disorder and symptoms similar to a seizure aura. If possible, this should include high resolution MRI (with particular attention paid to the mesial temporal cortex) and nuclear imaging. Future studies utilizing new technologies may assist in distinguishing these two entities or in further defining their common pathological base. Nuclear imaging may prove helpful in this endeavor, as very early work may indicate divergent scan findings—especially with receptor-specific ligands.

Cover

From Veterans Affairs Mid Atlantic Mental Illness Research, Education, and Clinical Center (R.A.H., K.H.T.); the Mental Health Service Line, Salisbury Veterans Affairs Medical Center, Salisbury, North Carolina (R.A.H., K.H.T.); Department of Radiology, Baylor College of Medicine, Houston, Texas (R.F.); Departments of Psychiatry and Radiology, Wake Forest University School of Medicine, Winston-Salem, North Carolina (R.A.H.); the Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, Texas (R.A.H.); and the Department of Physical Medicine and Rehabilitation, Baylor College of Medicine, Houston, Texas (K.H.T). Address correspondence to Dr. Robin Hurley, Hefner VA Medical Center, 1601 Brenner Ave., Salisbury, NC 28144; [email protected] (E-mail).

Copyright © American Psychiatric Publishing, Inc.

References

1. Watson Laboratories, Andermann F, Gloor P, et al: Anatomic basis of amygdaloid and hippocampal volume measurement by MRI. Neurology 1992; 42:1743–1750Google Scholar

2. Watson Laboratories, Jack CR Jr, Cendes F: Volumetric MRI: clinical applications and contributions to the understanding of temporal lobe epilepsy. Arch Neurol 1997; 54:1521–1531Google Scholar

3. Lee YS, Hwang J, Kim SJ, et al: Decreased blood flow of temporal regions of the brain in subjects with panic disorder. J Psychiatr Res 2006; 40:828–834Google Scholar

4. Sakai Y, Kumano H, Nishikawa M, et al: Cerebral glucose metabolism associated with a fear network in panic disorder. Neuroreport 2005; 16:927–931Google Scholar

5. Eren I, Tukel R, Polat A, et al: Evaluation of regional cerebral blood flow changes in panic disorder with technetium-99m-HMPAO SPECT. Psychiatr Res 2003; 123:135–143Google Scholar

6. Bisaga A, Katz JL, Antonini A, et al: Cerebral glucose metabolism in women with panic disorder. Am J Psychiatry 1998; 155:1178–1183Google Scholar

7. Toni C, Cassano GB, Perugi G, et al: Psychosensorial and related phenomena in panic disorder and in temporal lobe epilepsy. Compr Psychiatry 1996; 37:125–133Google Scholar

8. Sazgar M, Carlen PL, Wennberg R: Panic attack semiology in right temporal lobe epilepsy. Epileptic Disord 2003; 5:93–100Google Scholar

9. Young GB, Chandarana PC, Blume WT, et al: Mesial temporal lobe seizures presenting as anxiety disorders. J Neuropsychiatry Clin Neurosci 1995; 7:352–357Google Scholar

10. Mintzer S, Lopez F: Comorbidity of ictal fear and panic disorder. Epilepsy Behav 2002; 3:330–337Google Scholar

11. Young AW, Aggleton JP, Hellawell DJ, et al: Face processing impairments after amygdalotomy. Brain 1995; 118:15–24Google Scholar

12. Katon WJ: Clinical practice: panic disorder. N Engl J Med 2006; 354:2360–2367Google Scholar

13. Henry TR, Van Heertum RL: Positron emission tomography and single photon emission computed tomography in epilepsy care. Semin Nucl Med 2003; 33:88–104Google Scholar

14. Scalise A, Placidi F, Diomedi M, et al: Panic disorder or epilepsy? A case report. J Neurol Sci 2006; 246:173–175Google Scholar

15. Saegusa S, Takashashi T, Moriya J, et al: Panic attack symptoms in a patient with left temporal lobe epilepsy. J Int Med Res 2004; 32:64–96Google Scholar

16. Huppertz HJ, Schulze-Bonhage A: Distinguishing between partial seizures and panic attacks: epileptic panic attacks are not limited to adults. BMJ 2001; 322:864Google Scholar

17. Meyer MA, Zimmerman AW, Miller CA: Temporal lobe epilepsy presenting as panic attacks: detection of interictal hypometabolism with positron emission tomography. J Neuroimaging 2000; 10:120–122Google Scholar

18. Alemayehu S, Bergey GK, Barry E, et al: Panic attacks as ictal manifestations of parietal lobe seizures. Epilepsia 1995; 36:824–830Google Scholar

19. Alvarez-Silva S, Alvarez-Rodriguez J, Perez-Echeverria MJ, et al: Panic and epilepsy. J Anxiety Disord 2006; 20:353–362Google Scholar

20. Huppertz HJ, Franck P, Korinthenberg R, et al: Recurrent attacks of fear and visual hallucinations in a child. J Child Neurol 2002; 17:230–233Google Scholar

21. Blume WT, Holloway GM, Wiebe S: Temporal epileptogenesis: localizing value of scalp and subdural interictal and ictal EEG data. Epilepsia 2001; 42:508–514Google Scholar

22. McBride MC, Bronstein KS, Bennett B, et al: Failure of standard MRI in patients with refractory temporal lobe epilepsy. Arch Neurol 1998; 55:346–348Google Scholar

23. Van Paesschen W: Qualitative and quantitative imaging of the hippocampus in mesial temporal lobe epilepsy with hippocampal sclerosis. Neuroimaging Clin N Am 2004; 14:373–400Google Scholar

24. Hurley RA, Hayman LA, Taber KH: Clinical imaging in neuropsychiatry, in The American Psychiatric Press Textbook of Neuropsychiatry. Edited by Yudofsky SC, Hales RE. Washington, DC, American Psychiatric Publishing, 2002, pp 245–283Google Scholar

25. Lanteaume L, Khalfa S, Regis J, et al: Emotion induction after direct intracerebral stimulations of human amygdala. Cereb Cortex 2006 (e-pub ahead of print)Google Scholar

26. Fish DR, Gloor P, Quesney FL, et al: Clinical responses to electrical brain stimulation of the temporal and frontal lobes in patients with epilepsy. Brain 1993; 116:397–414Google Scholar

27. Halgren E, Walter RD, Cherlow DG, et al: Mental phenomena evoked by electrical stimulation of the human hippocampal formation and amygdala. Brain 1978; 101:83–117Google Scholar

28. Wieser HG: Electroclinical Features of the Psychomotor Seizure. New York, Raven Press, 1983Google Scholar

29. Penfield W, Jasper W: Epilepsy and the Functional Anatomy of the Human Brain. Boston, Little, Brown and Company, 1954Google Scholar

30. Biraben A, Taussig D, Thomas P, et al: Fear as the main feature of epileptic seizures. J Neurol Neurosurg Psychiatry 2001; 70:186–191Google Scholar

31. Schauble B, Cascino GD: Advances in neuroimaging: management of partial epileptic syndromes. Neurosurg Rev 2003; 26:233–246Google Scholar

32. Cendes F, Andermann F, Gloor P, et al: Relationship between atrophy of the amygdala and ictal fear in temporal lobe epilepsy. Brain 1994; 117:739–746Google Scholar

33. Guerreiro C, Cendes F, Li LM, et al: Clinical patterns of patients with temporal lobe epilepsy and pure amygdalar atrophy. Epilepsia 1999; 40:453–461Google Scholar

34. Massana G, Serra-Grabulosa JM, Salgado-Pineda P, et al: Amygdalar atrophy in panic disorder patients detected by volumetric MRI. Neuroimage 2003; 19:80–90Google Scholar

35. Uchida RR, Del-Ben CM, Santos AC, et al: Decreased left temporal lobe volume of panic patients measured by MRI. Braz J Med Biol Res 2003; 36:7925–7929Google Scholar

36. Vythilingam M, Anderson ER, Goddard A, et al: Temporal lobe volume in panic disorder—a quantitative MRI study. Psychiatry Res 2000; 99:75–82Google Scholar

37. Protopopescu X, Pan H, Tuescher O, et al: Increased brainstem volume in panic disorder: a voxel-based morphometric study. Neuroreport 2006; 17:361–363Google Scholar

38. Yoo HK, Kim MJ, Kim SJ, et al: Putaminal gray matter volume decrease in panic disorder: an optimized voxel-based morphometry study. Eur J Neurosci 2005; 22:2089–2094Google Scholar

39. Massana G, Serra-Grabulosa JM, Salgado-Pineda P, et al: Parahippocampal gray matter density in panic disorder: a voxel-based morphometric study. Am J Psychiatry 2003; 160:566–568Google Scholar

40. Breier JI, Mullani NA, Thomas AB, et al: Effects of duration of epilepsy on the uncoupling of metabolism and blood flow in complex partial seizures. Neurology 1997; 48:1047–1053Google Scholar

41. Lee DS, Lee JS, Kang KW, et al: Disparity of perfusion and glucose metabolism of epileptogenic zones in temporal lobe epilepsy demonstrated by SPM/SPAM analysis on 150 water PET, [fluorine-18]FDG-PET, and [technetium-99m]-HMPAO SPECT. Epilepsia 2001; 42:1515–1522Google Scholar

42. Gallinat J, Stotz-Ingenlath G, Lang UE, et al: Panic attacks, spike-wave activity, and limbic dysfunction: a case report. Pharmacopsychiatry 2003; 36:123–126Google Scholar

43. Tae WS, Joo EY, Kim JH, et al: Cerebral perfusion changes in mesial temporal lobe epilepsy: SPM analysis of ictal and interictal SPECT. Neuroimage 2005; 24:101–110Google Scholar

44. Choi JY, Kim SJ, Hong SB, et al: Extratemporal hypometabolism on FDG PET in temporal lobe epilepsy as a predictor of seizure outcome after temporal lobectomy. Eur J Nucl Med Mol Imaging 2003; 30:581–587Google Scholar

45. Sakai Y, Kumano H, Nishikawa M, et al: Changes in cerebral glucose utilization in patients with panic disorder treated with cognitive behavior therapy. Neuroimage 2006; 33:218–226Google Scholar

46. Roy-Byrne PP: The GABA-benzodiazepine receptor complex: structure, function, and role in anxiety. J Clin Psychiatry 2005; 66:14–20Google Scholar

47. Avoli M, Lauvel J, Pumain R, et al: Cellular and molecular mechanisms of epilepsy in the human brain. Prog Neurobiol 2005; 77: 166–200Google Scholar

48. Goethals I, Van de Wiele C, Boon P, et al: Is central benzodiazepine receptor imaging useful for the identification of epileptogenic foci in localization-related epilepsies? Eur J Nucl Med Mol Imaging 2003; 30:325–328Google Scholar

49. Sata Y, Matsuda K, Mihara T, et al: Quantitative analysis of benzodiazepine receptor in temporal lobe epilepsy: [(125)I] iomazenil autoradiographic study of surgically resected specimens. Epilepsia 2002; 43:1039–1048Google Scholar

50. Ryvlin P, Bouvard S, Le Bars D, et al: Clinical utility of flumazenil-PET [fluorine-18] fluorodeoxyglucose-PET and MRI in refractory partial epilepsy: a prospective study in 100 patients. Brain 1998; 121:2067–2081Google Scholar

51. Cascino GD: Measurement and significance of change in benzodiazepine receptors in temporal lobe epilepsy. Epilepsy Curr 2003; 3:33–34Google Scholar

52. Morimoto K, Tamagami H, Matsuda K: Central-type benzodiazepine receptors and epileptogenesis: basic mechanisms and clinical validity. Epilepsia 2005; 45:184–188Google Scholar

53. Shuke N, Hashizume K, Kiriyama K, et al: Correct localization of epileptogenic focus with iodine-123 iomazenil cerebral benzodiazepine receptor imaging: a case report of temporal lobe epilepsy with discordant ictal cerebral blood flow SPECT. Ann Nucl Med 2004; 18:541–545Google Scholar

54. Bouvard S, Costes N, Bonnefoi F, et al: Seizure-related short-term plasticity of benzodiazepine receptor in partial epilepsy: a [carbon-11] fumazenil-PET study. Brain 2005; 128:1330–1343Google Scholar

55. Malizia AL, Cunningham VJ, Bell CJ, et al: Decreased brain GABAA-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch Gen Psychiatry 1998; 55:715–720Google Scholar

56. Brandt CA, Meller J, Keweloh L, et al: Increased benzodiazepine receptor density in the prefrontal cortex in patients with panic disorder. J Neural Transm 1998; 105:1325–1333Google Scholar

57. Bremner JD, Innis RB, White T, et al: SPECT[iodine-123] iomazenil measurement of the benzodiazepine receptor in panic disorder. Biol Psychiatry 2000; 47:96–106Google Scholar

58. Bremner JD, Narayan M, Anderson ER, et al: Hippocampal volume reduction in major depression. Am J Psychiatry 2000; 157:115–117Google Scholar

59. Chugani HT, Chugani DC: Imaging of serotonin mechanisms in epilepsy. Epilepsy Curr 2005; 5:201–206Google Scholar

60. Maron E, Shlik J: Serotonin function in panic disorder: important, but why? Neuropsychopharmacology 2006; 31:1–11Google Scholar

61. Toczek MT, Carsons RE, Lang L, et al: PET imaging of 5-HT1A receptor binding in patients with temporal lobe epilepsy. Neurology 2003; 60:749–756Google Scholar

62. Savic I, Lindstrom P, Gulyas B, et al: Limbic reductions of 5-HT1A receptor binding in human temporal lobe epilepsy. Neurology 2004; 62:1343–1351Google Scholar

63. Merlet I, Ostrowsky K, Costes N, et al: 5-HT1A receptor binding and intracerebral activity in temporal lobe epilepsy: an [fluorine-18]MPPF-PET study. Brain 2004; 127:900–913Google Scholar

64. Merlet I, Ryvlin P, Costes N, et al: Statistical parametric mapping of 5-HT1A receptor binding in temporal lobe epilepsy with hippocampal ictal onset on intracranial EEG. Neuroimage 2004; 22:886–896Google Scholar

65. Giovacchini G, Toczek MT, Bonwetsch R, et al: 5-HT1A receptors are reduced in temporal lobe epilepsy after partial-volume correction. J Nucl Med 2005; 46:1128–1135Google Scholar

66. Theodore WH, Giovacchini G, Bonwetsch R, et al: The effect of antiepileptic drugs on 5-HT1A-receptor binding measured by positron emission tomography. Epilepsia 2006; 47:499–503Google Scholar

67. Neumeister A, Bain E, Nugent AC, et al: Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci 2004; 24:589–591Google Scholar

68. Nash JR, Sargent PA, Rabiner EA, et al: Altered 5HT1A binding in panic disorder demonstrated by positron emission tomography. Eur Neuropsychopharmacol 2004; 14:322–323Google Scholar